COEP — Coeptis Therapeutics Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $74.14m
- $73.43m
Annual cashflow statement for Coeptis Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.3 | 15.2 | -37.6 | -21.3 | -10.9 |
| Depreciation | |||||
| Non-Cash Items | 17.2 | -15.9 | 33.2 | 11.2 | 3.08 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.047 | 0.178 | -0.55 | 1.8 | 0.109 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -0.116 | -0.503 | -3.88 | -7.24 | -6.65 |
| Other Investing Cash Flow Items | -75.8 | — | 0 | 0 | 0 |
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -75.8 | — | 0 | 0 | 0 |
| Financing Cash Flow Items | -0.325 | 0 | -0.615 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 76.8 | 0 | 5.49 | 4.92 | 5.71 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.907 | -0.503 | 1.61 | -2.32 | -0.936 |